罗氟司特对亚洲慢性阻塞性肺疾病患者肺功能影响的Meta分析(5)
[19] LIU DY，WANG ZG，GAO Y，et al. Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients[J]. Medicine，2018. DOI：10.1097/MD. 0000000000009864.
[20] FIELD SK. Roflumilast，a novel phosphodiesterase 4 inhibitor，for COPD Patients with a History of exacerbations[J]. Clin Med Insights Circ Respir Pulm Med，2011. DOI：10.4137/CCRPM.S7049.
[21] YASUDA SU，ZHANG L，HUANG SM. The role of ethnicity in variability in response to drugs：focus on clinical pharmacology studies[J]. Clin Pharmacol Ther，2008，84(3)：417-423.
[22] CHONG J，POOLE P，LEUNG B，et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev，2011. DOI：10.1002/14651858.CD002309.
[23] RENNARD SI，MARTINEZ FJ，RABE KF，et al. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination：RE(2)SPOND rationale and study design[J]. Int J Chron Obstruct Pulmon Dis，2016. DOI：10.2147/COPD.S109661.
(收稿日期：2018-11-01 修回日期：2019-03-04)
(編辑：陈 宏), http://www.100md.com(程莎 代泽兰 肖创 翁稚颖 饶嫱 王红艳 杨为民)
[20] FIELD SK. Roflumilast，a novel phosphodiesterase 4 inhibitor，for COPD Patients with a History of exacerbations[J]. Clin Med Insights Circ Respir Pulm Med，2011. DOI：10.4137/CCRPM.S7049.
[21] YASUDA SU，ZHANG L，HUANG SM. The role of ethnicity in variability in response to drugs：focus on clinical pharmacology studies[J]. Clin Pharmacol Ther，2008，84(3)：417-423.
[22] CHONG J，POOLE P，LEUNG B，et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev，2011. DOI：10.1002/14651858.CD002309.
[23] RENNARD SI，MARTINEZ FJ，RABE KF，et al. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination：RE(2)SPOND rationale and study design[J]. Int J Chron Obstruct Pulmon Dis，2016. DOI：10.2147/COPD.S109661.
(收稿日期：2018-11-01 修回日期：2019-03-04)
(編辑：陈 宏), http://www.100md.com(程莎 代泽兰 肖创 翁稚颖 饶嫱 王红艳 杨为民)